Loading

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support

PeerCurrent

PcPeerCurrent

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Set your cadence Alerts Settings Help

Back to follows

Researcher

Hao-Cheng Hsu

Taipei Medical University

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials Reviews Guidelines

Latest

Everything in the corpus, newest first.

SEP 5, 2026 · JOURNAL ARTICLE

A CD44-targeted PDA/ZnO redox-active nanocomposite that couples chemotherapy with mitochondrial stress and tumor immune remodeling

Journal of Nanobiotechnology

Early-stage in vivo proof-of-concept in a single model system with no control arm comparison, surrogate endpoints, and no clinical translation data reported.

PreliminaryYao-En Cai Kai-Yi Tzou Hao-Cheng Hsu

Study details

DesignPreclinical in vivo proof-of-concept study

InterventionCD44-targeted nanocomposite (HPPZC) compris…

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support